Tremfya and Dermatitis exfoliative generalised - a phase IV clinical study of FDA data

Summary:

Dermatitis exfoliative generalised is reported as a side effect among people who take Tremfya (guselkumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Betamethasone Dipropionate, and have Psoriasis.

The phase IV clinical study analyzes which people have Dermatitis exfoliative generalised when taking Tremfya. It is created by eHealthMe based on reports of 22,544 people who have side effects when taking Tremfya from the FDA, and is updated regularly.

What is Tremfya?

Tremfya has active ingredients of guselkumab. eHealthMe is studying from 22,557 Tremfya users. Check the latest studies of Tremfya.

What is Dermatitis exfoliative generalised?

Dermatitis exfoliative generalised (inflammatory skin disease with erythema and scaling that affects nearly the entire cutaneous surface) is found to be associated with 263 drugs and 198 conditions by eHealthMe. Check the latest studies of Dermatitis exfoliative generalised.

On Jul, 31, 2026

22,544 people reported to have side effects when taking Tremfya.
Among them, 18 people (0.08%) have Dermatitis exfoliative generalised.

Could Tremfya cause Dermatitis exfoliative generalised?

Among these 18 people:

How long have people been on Tremfya when they have Dermatitis exfoliative generalised? *

What is the gender of people who have Dermatitis exfoliative generalised when taking Tremfya? *

female: 22.22 %
male: 77.78 %

What is the age of people who have Dermatitis exfoliative generalised when taking Tremfya? *

What are other drugs people take besides Tremfya? *

Otezla: 2 people, 11.11%
Betamethasone Dipropionate: 2 people, 11.11%
Stelara: 1 person, 5.56%
Silvadene: 1 person, 5.56%
Metformin: 1 person, 5.56%
Humira: 1 person, 5.56%

What are other side effects people have besides Dermatitis exfoliative generalised? *

Drug Hypersensitivity: 2 people, 11.11%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 1 person, 5.56%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 5.56%
Pneumonia: 1 person, 5.56%
Pancreatitis (inflammation of pancreas): 1 person, 5.56%
Muscle Aches (muscle pain): 1 person, 5.56%
Malaise (a feeling of general discomfort or uneasiness): 1 person, 5.56%
Inflammatory Marker Increased: 1 person, 5.56%
Hyperhidrosis (abnormally increased sweating): 1 person, 5.56%
General Physical Condition Abnormal: 1 person, 5.56%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 9 people, 50.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 11.11%
Wound: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Tremfya and have Dermatitis exfoliative generalised?

- Check whether Dermatitis exfoliative generalised is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tremfya:

Tremfya (22,557 reports)

Browse all side effects of Tremfya:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis exfoliative generalised:

Dermatitis exfoliative generalised (263 drugs)

Browse all the conditions that are associated with Dermatitis exfoliative generalised:

Dermatitis exfoliative generalised (198 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on guselkumab (the active ingredients of Tremfya) and Tremfya (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.